Ribavirin improves early responses to peginterferon through improved interferon signaling.
Feld
Jordan J
JJ
Liver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland 20892-1800, USA.
Lutchman
Glen A
GA
Heller
Theo
T
Hara
Koji
K
Pfeiffer
Julie K
JK
Leff
Richard D
RD
Meek
Claudia
C
Rivera
Maria
M
Ko
Myung
M
Koh
Christopher
C
Rotman
Yaron
Y
Ghany
Marc G
MG
Haynes-Williams
Vanessa
V
Neumann
Avidan U
AU
Liang
T Jake
TJ
Hoofnagle
Jay H
JH
D000328:Adult; D000368:Aged; D000998:Antiviral Agents / Q000494:pharmacology*; D054357:Chemokine CXCL10 / Q000097:blood; D005260:Female; D019698:Hepatitis C, Chronic / Q000188:drug therapy* / Q000821:virology; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000008:administration & dosage / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D009154:Mutation; D011092:Polyethylene Glycols / Q000008:administration & dosage / Q000627:therapeutic use*; D012367:RNA, Viral / Q000097:blood; D011994:Recombinant Proteins; D012254:Ribavirin / Q000097:blood / Q000494:pharmacology*; D015398:Signal Transduction / Q000187:drug effects*; D016896:Treatment Outcome
D000998:Antiviral Agents; C114753:CXCL10 protein, human; D054357:Chemokine CXCL10; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D012367:RNA, Viral; D011994:Recombinant Proteins; D011092:Polyethylene Glycols; D012254:Ribavirin; C100416:peginterferon alfa-2a